A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

When an insurance denial blocks guest writer Denise Schnieders from getting an MS disease activity test, she decides to fight back.

LONDON — Previous research has shown that providing a clinically definite multiple sclerosis (MS) diagnosis often takes several weeks or even months. But new research suggests that a new "technology ...

A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of ...

Scientists have found blood protein signals that may flag multiple sclerosis up to seven years before symptoms begin. Spotting early warning signs means more opportunities to treat or prevent multiple ...

Publication in the journal ‘Brain’ confirms complementary roles of the biomarkers for predicting relapse and chronic disability progression in multiple sclerosis (MS) Simoa technology paired with an ...

Real-world data show increasing clinical use of blood-based biomarker panels to monitor disease activity and treatment response in multiple sclerosis.

Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States Collaboration ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...